These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16391157)

  • 1. Myocardial viability testing and the effect of early intervention in patients with advanced left ventricular systolic dysfunction.
    Tarakji KG; Brunken R; McCarthy PM; Al-Chekakie MO; Abdel-Latif A; Pothier CE; Blackstone EH; Lauer MS
    Circulation; 2006 Jan; 113(2):230-7. PubMed ID: 16391157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imaging.
    Beanlands RS; Hendry PJ; Masters RG; deKemp RA; Woodend K; Ruddy TD
    Circulation; 1998 Nov; 98(19 Suppl):II51-6. PubMed ID: 9852880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: inducible ischemia versus hibernating myocardium.
    Ling LF; Marwick TH; Flores DR; Jaber WA; Brunken RC; Cerqueira MD; Hachamovitch R
    Circ Cardiovasc Imaging; 2013 May; 6(3):363-72. PubMed ID: 23595888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome of patients with previous myocardial infarction and left ventricular dysfunction assessed with myocardial (99m)Tc-MIBI SPECT and (18)F-FDG PET.
    Zhang X; Liu XJ; Wu Q; Shi R; Gao R; Liu Y; Hu S; Tian Y; Guo S; Fang W
    J Nucl Med; 2001 Aug; 42(8):1166-73. PubMed ID: 11483675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial.
    D'Egidio G; Nichol G; Williams KA; Guo A; Garrard L; deKemp R; Ruddy TD; DaSilva J; Humen D; Gulenchyn KY; Freeman M; Racine N; Benard F; Hendry P; Beanlands RS;
    JACC Cardiovasc Imaging; 2009 Sep; 2(9):1060-8. PubMed ID: 19761983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: the Ottawa-FIVE substudy of the PARR 2 trial.
    Abraham A; Nichol G; Williams KA; Guo A; deKemp RA; Garrard L; Davies RA; Duchesne L; Haddad H; Chow B; DaSilva J; Beanlands RS;
    J Nucl Med; 2010 Apr; 51(4):567-74. PubMed ID: 20237039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2).
    Beanlands RS; Nichol G; Huszti E; Humen D; Racine N; Freeman M; Gulenchyn KY; Garrard L; deKemp R; Guo A; Ruddy TD; Benard F; Lamy A; Iwanochko RM;
    J Am Coll Cardiol; 2007 Nov; 50(20):2002-12. PubMed ID: 17996568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic performance of quantitative PET tools for stratification of patients with ischemic cardiomyopathy undergoing myocardial viability assessment.
    Santana CA; Faber TL; Soler-Peter M; Sanyal R; Esteves FP; Ornelas M; Folks RD; Verdes L; Santana LF; Candell-Riera J; Garcia EV
    Nucl Med Commun; 2008 Nov; 29(11):970-81. PubMed ID: 18836375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of contrast-enhanced MRI with (18)F-FDG PET/201Tl SPECT in dysfunctional myocardium: relation to early functional outcome after surgical revascularization in chronic ischemic heart disease.
    Wu YW; Tadamura E; Yamamuro M; Kanao S; Marui A; Tanabara K; Komeda M; Togashi K
    J Nucl Med; 2007 Jul; 48(7):1096-103. PubMed ID: 17607039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Follow-Up of Outcomes With F-18-Fluorodeoxyglucose Positron Emission Tomography Imaging-Assisted Management of Patients With Severe Left Ventricular Dysfunction Secondary to Coronary Disease.
    Mc Ardle B; Shukla T; Nichol G; deKemp RA; Bernick J; Guo A; Lim SP; Davies RA; Haddad H; Duchesne L; Hendry P; Masters R; Ross H; Freeman M; Gulenchyn K; Racine N; Humen D; Benard F; Ruddy TD; Chow BJ; Mielniczuk L; DaSilva JN; Garrard L; Wells GA; Beanlands RS;
    Circ Cardiovasc Imaging; 2016 Sep; 9(9):. PubMed ID: 27609816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of diabetes mellitus on prediction of clinical outcome after coronary revascularization by 18F-FDG SPECT in patients with ischemic left ventricular dysfunction.
    Schinkel AF; Poldermans D; Rizzello V; van Domburg RT; Valkema R; Elhendy A; Biagini E; Krenning EP; Simoons ML; Bax JJ
    J Nucl Med; 2006 Jan; 47(1):68-73. PubMed ID: 16391189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial perfusion reserve after a PET-driven revascularization procedure: a strong prognostic factor.
    Slart RH; Zeebregts CJ; Hillege HL; de Sutter J; Dierckx RA; van Veldhuisen DJ; Zijlstra F; Tio RA
    J Nucl Med; 2011 Jun; 52(6):873-9. PubMed ID: 21571798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of myocardial viability and coronary revascularization on clinical outcome and prognosis: a follow-up study of 161 patients with coronary heart disease].
    vom Dahl J; Altehoefer C; Büchin P; Sheehan FH; Schwarz ER; Koch KC; Schulz G; Uebis R; Schöndube F; Messmer BJ; Büll U; Hanrath P
    Z Kardiol; 1996 Nov; 85(11):868-81. PubMed ID: 9064949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of myocardial viability by delayed-enhanced magnetic resonance in patients with coronary artery disease and low ejection fraction: impact of revascularization therapy.
    Gerber BL; Rousseau MF; Ahn SA; le Polain de Waroux JB; Pouleur AC; Phlips T; Vancraeynest D; Pasquet A; Vanoverschelde JL
    J Am Coll Cardiol; 2012 Feb; 59(9):825-35. PubMed ID: 22361403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The extent of perfusion-F18-fluorodeoxyglucose positron emission tomography mismatch determines mortality in medically treated patients with chronic ischemic left ventricular dysfunction.
    Desideri A; Cortigiani L; Christen AI; Coscarelli S; Gregori D; Zanco P; Komorovsky R; Bax JJ
    J Am Coll Cardiol; 2005 Oct; 46(7):1264-9. PubMed ID: 16198841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of five-year outcomes of coronary artery bypass grafting versus percutaneous coronary intervention in patients with left ventricular ejection fractions≤50% versus >50% (from the CREDO-Kyoto PCI/CABG Registry Cohort-2).
    Marui A; Kimura T; Nishiwaki N; Mitsudo K; Komiya T; Hanyu M; Shiomi H; Tanaka S; Sakata R;
    Am J Cardiol; 2014 Oct; 114(7):988-96. PubMed ID: 25124184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myocardial positive pre-ejection velocity accurately detects presence of viable myocardium, predicts recovery of left ventricular function and bears a prognostic value after surgical revascularization.
    Penicka M; Tousek P; De Bruyne B; Wijns W; Lang O; Madaric J; Vanderheyden M; Tintera J; Malý M; Widimsky P; Bartunek J
    Eur Heart J; 2007 Jun; 28(11):1366-73. PubMed ID: 17208936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomography using(18)F-fluoro-deoxyglucose and euglycaemic hyperinsulinaemic glucose clamp: optimal criteria for the prediction of recovery of post-ischaemic left ventricular dysfunction. Results from the European Community Concerted Action Multicenter study on use of(18)F-fluoro-deoxyglucose Positron Emission Tomography for the Detection of Myocardial Viability.
    Gerber BL; Ordoubadi FF; Wijns W; Vanoverschelde JL; Knuuti MJ; Janier M; Melon P; Blanksma PK; Bol A; Bax JJ; Melin JA; Camici PG
    Eur Heart J; 2001 Sep; 22(18):1691-701. PubMed ID: 11511119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of outcome and cost-effectiveness using an FDG PET-guided approach to management of patients with coronary disease and severe left ventricular dysfunction (PARR-2): rationale, design, and methods.
    Beanlands R; Nichol G; Ruddy TD; deKemp RA; Hendry P; Humen D; Racine N; Ross H; Benard F; Coates G; Iwanochko RM; Fallen E; Wells G;
    Control Clin Trials; 2003 Dec; 24(6):776-94. PubMed ID: 14662282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extensive left ventricular remodeling does not allow viable myocardium to improve in left ventricular ejection fraction after revascularization and is associated with worse long-term prognosis.
    Bax JJ; Schinkel AF; Boersma E; Elhendy A; Rizzello V; Maat A; Roelandt JR; van der Wall EE; Poldermans D
    Circulation; 2004 Sep; 110(11 Suppl 1):II18-22. PubMed ID: 15364832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.